We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab.
- Authors
Sun, Yng; Lin, Sheng Yiao; Lan, Cheng‐Che E.
- Abstract
Chronic urticaria (CU) is a mast cell (MC)-driven disease characterized by the development of wheals, angioedema, or both for more than 6 weeks. It has been postulated that MC-degranulating signals involving immunoglobulin-E (IgE) autoantibodies may be implicated in patients with CU.2,3 Patients with refractory CU are experiencing complete remission for the first time, thanks to the use of omalizumab, an IgG monoclonal antibody that inhibits IgE binding to the high-affinity IgE receptors on MCs.
- Subjects
URTICARIA; DUPILUMAB; OMALIZUMAB; MAST cells; WEIGHT gain; MONOCLONAL antibodies
- Publication
Kaohsiung Journal of Medical Sciences, 2022, Vol 38, Issue 6, p610
- ISSN
1607-551X
- Publication type
Article
- DOI
10.1002/kjm2.12531